title: What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting?
abstract: The new mantra for delivering optimal cancer treatment is "personalized care." This extends beyond the holistic to using germline and somatic tumoral mutations to link a specific therapy to some prognostic or predictive factor which defines a particularly responsive patient subgroup who might benefit most from treatment. Furthermore, inherited polymorphisms have the potential to greatly modulate the side effects of treatment, especially for chemotherapy which has a notoriously narrow therapeutic window.
authors.affiliation: Sidra Medical and Research Centre, Qatar Foundation, Doha, Qatar.
authors.forename: Haitham M
authors.initials: HM
authors.lastname: Al-Salama
authors.forename: Elaine C
authors.initials: EC
authors.lastname: Johnstone
authors.forename: David James
authors.initials: DJ
authors.lastname: Kerr
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D055106:Genome-Wide Association Study; D042822:Genomic Instability / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods; D057285:Precision Medicine / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor